Establishment Labs Holdings Inc. ESTA

Company Overview

Establishment Labs Holdings Inc. is a Costa Rica–based medical technology company focused on aesthetic and reconstructive plastic surgery products, primarily breast implants and related surgical technologies. The company operates within the global medical aesthetics and medical device industries and is best known for its Motiva-branded breast implant platform, which includes silicone gel-filled implants designed for breast augmentation and reconstruction procedures. Revenue is primarily generated through sales of breast implants, tissue expanders, and complementary surgical products sold to plastic surgeons, hospitals, and aesthetic clinics.

The company positions itself as a technology-focused innovator in breast aesthetics, emphasizing product safety, ergonomic design, and digital integration. A key differentiator has been the development of Motiva implants featuring proprietary technologies such as SmoothSilk surface technology and embedded RFID-enabled implant traceability in certain products. Establishment Labs was founded in 2004 by Juan José Chacón-Quirós and initially concentrated on international markets outside the United States. Over time, the company expanded globally and pursued regulatory approvals across Europe, Latin America, Asia-Pacific, and more recently the U.S. market through the FDA approval process for Motiva implants.

Business Operations

Establishment Labs primarily operates through its Motiva product ecosystem, which includes breast implants, tissue expanders, and related aesthetic technologies. The company reports revenue largely from direct sales and distributor-based sales of implant products in international markets. Historically, a substantial portion of sales has originated outside the United States, particularly in Latin America, Europe, and Asia-Pacific. The company has also expanded into minimally invasive aesthetic technologies and digital surgery-related solutions associated with breast procedures.

The company controls manufacturing operations through facilities in Costa Rica and maintains vertically integrated capabilities related to implant design, production, quality control, and regulatory compliance. Establishment Labs has also invested in complementary platforms such as Mia Femtech, a minimally invasive breast enhancement approach, and technologies tied to procedural planning and patient monitoring. Partnerships with distributors, surgeons, and clinical institutions support market penetration across multiple regions. Public filings and investor materials indicate the company has continued investing in clinical trials, regulatory approvals, and commercialization infrastructure to support expansion.

Strategic Position & Investments

Establishment Labs’ strategic direction has centered on expanding the global adoption of the Motiva platform while increasing penetration in the U.S. market following FDA-related milestones. Growth initiatives have included physician education programs, investment in clinical evidence, expansion of direct sales infrastructure, and broader commercialization of minimally invasive breast enhancement procedures. The company has also emphasized premium positioning within the breast aesthetics market through branding, product differentiation, and safety-focused technology.

Major investments have included manufacturing expansion, research and development activities, and clinical programs designed to support regulatory approvals and long-term product validation. The company has highlighted strategic interest in emerging sectors that combine aesthetics, digital health, and women’s health technology. Establishment Labs has also developed or supported platforms including Mia Femtech and related procedural technologies intended to broaden the company’s role beyond traditional implants. Public disclosures indicate ongoing investment in innovation-driven growth rather than diversification into unrelated healthcare categories.

Geographic Footprint

Establishment Labs is headquartered in Alajuela, Costa Rica, and maintains a broad international commercial footprint spanning more than 80 countries according to company disclosures and regulatory filings. The company has established significant market presence across Europe, Latin America, Asia-Pacific, and the Middle East, with increasing strategic emphasis on the United States following regulatory progress for Motiva implants. International sales have historically represented the majority of company revenue.

The company operates through a combination of direct commercial teams and third-party distributors depending on the region. Manufacturing and operational infrastructure remain centered in Costa Rica, while commercial and regulatory functions support expansion across major aesthetic surgery markets globally. Establishment Labs’ international positioning has been a defining characteristic of its business model, particularly during periods when its flagship implant products were commercially available in numerous overseas markets prior to broader U.S. commercialization.

Leadership & Governance

Establishment Labs was founded by Juan José Chacón-Quirós, who has remained closely associated with the company’s strategic and technological direction. Leadership has consistently emphasized innovation, physician collaboration, patient safety, and premium product positioning within the global aesthetics market. Public company governance includes executive leadership with backgrounds in medical devices, commercialization, operations, and finance.

Key executives have included:

• Juan José Chacón-Quirós – Founder, Chief Executive Officer
• Robert Langert – Independent Chairman of the Board
• Marco A. Chacón – Chief Operating Officer
• Cynthia L. Benzing – Chief Financial Officer
• Steven Basta – Board Member
• M. Christine Jacobs – Board Member

Company leadership has communicated a long-term strategy focused on clinical validation, global regulatory expansion, and technology-led differentiation in aesthetic medicine. Governance practices and executive compensation structures are disclosed through public filings including SEC filings and annual reports.